Skip to main content
Expanded indication approved by FDA for Erleada for prostate cancer
9/19/2019

The FDA approved an expanded indication for Janssen's oral androgen receptor inhibitor Erleada, or apalutamide, with the addition of coverage for men with metastatic castration-sensitive prostate cancer.

Full Story: